Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC patients diagnosed with symptomatic bone metastasis and to collect additional short and long term safety data on the product.
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||Radium-223 Chloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01516762
Show 60 Study Locations
|Study Director:||Bayer Study Director||Bayer|